# Israel Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Israel HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Israel (ISR) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $2.8B - Products: 47 - Buyer markets: 30 - Average CAGR: +9.4% - Global sector size: $827.2B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $306.5B | $1.6B | $113.2B | +9.4% | 21 | +0.2% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $170.2B | $92.2M | $70.5B | +12.8% | 18 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $31.3B | $23.9M | $50.4B | +21.1% | 6 | +0.1% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $26.4B | $15.0M | $29.6B | +36.9% | 4 | +0.0% | | HS 300220 - Vaccines: for human medicine | $30.4B | $932.9K | $25.3B | +2.3% | 8 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $33.7M | $23.0B | +10.7% | 3 | +0.1% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $10.4K | $16.8B | -8.5% | 3 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $11.6M | $15.9B | +5.2% | 8 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $28.0B | $170.7M | $15.9B | +9.6% | 6 | +0.5% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.1B | $43.0M | $14.9B | +37.4% | 6 | +0.2% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $283.2K | $9.6B | +4.4% | 2 | +0.0% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $5.0B | $182.2K | $7.4B | +9.2% | 3 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $3.8M | $7.4B | +1.7% | 2 | +0.0% | | HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $3.0 | $6.7B | -34.3% | 1 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $13.5M | $6.3B | +13.8% | 3 | +0.1% | | HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $2.1M | $6.3B | -11.4% | 1 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $5.2M | $6.1B | +1.3% | 3 | +0.1% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $66.3M | $5.8B | +20.6% | 2 | +0.6% | | HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $10.1B | $504.7M | $5.7B | +10.0% | 3 | +4.9% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $5.0B | $262.2K | $5.6B | +8.8% | 3 | +0.0% | | HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $2.6B | $2.1K | $5.1B | +6.3% | 1 | +0.0% | | HS 290110 - Acyclic hydrocarbons: saturated | $2.9B | $1.8M | $5.1B | +11.9% | 2 | +0.1% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $6.6B | $1.5M | $4.9B | -15.2% | 3 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $21.8K | $4.8B | -0.9% | 1 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $5.6B | $482.3 | $4.3B | +23.7% | 2 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $70.6M | $4.0B | +7.7% | 2 | +0.7% | | HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $849.4 | $2.4B | +6.5% | 1 | +0.0% | | HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $1.5M | $2.4B | +28.1% | 1 | +0.1% | | HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $3.5K | $2.2B | +24.7% | 1 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $274.2K | $2.1B | +11.7% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $17.6M | $2.0B | +31.9% | 1 | +0.5% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $7.7M | $2.0B | +0.5% | 1 | +0.3% | | HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $423.7K | $1.9B | +14.9% | 1 | +0.0% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $86.7K | $1.9B | +1.2% | 1 | +0.0% | | HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $50.3 | $1.8B | -3.1% | 1 | +0.0% | | HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $898.7K | $1.8B | +14.1% | 1 | +0.0% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $1.9K | $1.8B | +31.5% | 1 | +0.0% | | HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $29.7M | $1.7B | +15.2% | 1 | +1.5% | | HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $300.9 | $1.7B | -51.0% | 1 | +0.0% | | HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $968.2 | $1.5B | -6.6% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $6.9 | $1.4B | -30.4% | 1 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $279.7 | $1.4B | -83.9% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $239.7K | $1.4B | +23.4% | 1 | +0.0% | | HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $7.8K | $1.3B | -10.0% | 1 | +0.0% | | HS 382370 - Industrial fatty alcohols | $1.0B | $402.7 | $1.3B | -18.0% | 1 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $38.6M | $1.2B | +45.6% | 1 | +2.1% | | HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $601.4K | $1.2B | +20.7% | 1 | +1.2% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $154.5B calculated opportunity across 23 products. - China (CHN): $49.4B calculated opportunity across 17 products. - Slovenia (SVN): $44.0B calculated opportunity across 7 products. - Germany (DEU): $39.1B calculated opportunity across 12 products. - Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products. - Belgium (BEL): $27.2B calculated opportunity across 5 products. - Italy (ITA): $23.9B calculated opportunity across 4 products. - Netherlands (NLD): $14.7B calculated opportunity across 4 products. - Canada (CAN): $13.1B calculated opportunity across 7 products. - United Kingdom (GBR): $11.1B calculated opportunity across 5 products. - Japan (JPN): $10.9B calculated opportunity across 4 products. - Spain (ESP): $10.4B calculated opportunity across 5 products. ## Growth stars - HS 300390: +45.6% average CAGR, $1.2B calculated opportunity. - HS 382499: +37.4% average CAGR, $14.9B calculated opportunity. - HS 300214: +36.9% average CAGR, $29.6B calculated opportunity. - HS 300420: +31.9% average CAGR, $2.0B calculated opportunity. - HS 370790: +31.5% average CAGR, $1.8B calculated opportunity. - HS 285390: +28.1% average CAGR, $2.4B calculated opportunity. - HS 290531: +24.7% average CAGR, $2.2B calculated opportunity. - HS 382600: +23.7% average CAGR, $4.3B calculated opportunity. - HS 340220: +23.4% average CAGR, $1.4B calculated opportunity. - HS 293719: +21.1% average CAGR, $50.4B calculated opportunity. ## Diversification opportunities - HS 300490: 21 buyer markets, $113.2B calculated opportunity. - HS 300215: 18 buyer markets, $70.5B calculated opportunity. - HS 300220: 8 buyer markets, $25.3B calculated opportunity. - HS 300439: 8 buyer markets, $15.9B calculated opportunity. - HS 293719: 6 buyer markets, $50.4B calculated opportunity. - HS 300212: 6 buyer markets, $15.9B calculated opportunity. - HS 382499: 6 buyer markets, $14.9B calculated opportunity. - HS 300214: 4 buyer markets, $29.6B calculated opportunity. - HS 293359: 3 buyer markets, $23.0B calculated opportunity. - HS 293399: 3 buyer markets, $16.8B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.